Alex Fotopoulos
Hoofd Techniek/Wetenschap/O&O bij PASSAGE BIO, INC.
Vermogen: 96 005 $ op 30-04-2024
Actieve functies van Alex Fotopoulos
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| PASSAGE BIO, INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2019 | - |
Loopbaan van Alex Fotopoulos
Eerdere bekende functies van Alex Fotopoulos
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Hoofd Techniek/Wetenschap/O&O | 01-11-2017 | 01-07-2019 |
| DIMENSION THERAPEUTICS INC | Hoofd Techniek/Wetenschap/O&O | 01-05-2016 | 01-11-2017 |
| MOMENTA PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-08-2011 | 01-05-2016 |
| BIOGEN INC. | Corporate Officer/Principal | 01-08-1994 | 01-01-2011 |
Opleiding van Alex Fotopoulos
| Tufts University | Graduate Degree |
| F.W. Olin Graduate School of Business | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 8 |
Operationeel
| Chief Tech/Sci/R&D Officer | 4 |
| Graduate Degree | 1 |
| Masters Business Admin | 1 |
Sectoraal
| Health Technology | 6 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| PASSAGE BIO, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Alex Fotopoulos
- Ervaring
